Kaiser Permanente
Division of Research Spotlight
The Kaiser Permanente Division of Research conducts, publishes, and disseminates epidemiologic and health services research to improve the health and medical care of Kaiser Permanente members and society at large. We seek to understand the determinants of illness and well-being, and to improve the quality and cost-effectiveness of health care. Currently, DOR’s 550-plus staff is working on more than 350 epidemiological and health services research projects.
Research presented at the American Society for Clinical Oncology annual meeting amplified the ways the Division of Research and The Permanente Medical Group advance cancer care.
About 75 children are scheduled to receive their first vaccination against COVID-19 as part of the Pfizer/BioNTech vaccine clinical trial through Kaiser Permanente Northern California.
COVID-19 patients who are not hospitalized are at low risk of developing blood clots and should not routinely be prescribed blood thinners, a new Kaiser Permanente research letter suggests.
Researchers and clinicians with Kaiser Permanente Northern California are developing a wide-ranging research agenda to beat COVID-19, working at the accelerated pace demanded by a worldwide pandemic.
Kaiser Permanente study is the first to compare early telehealth approach to early in-person follow-up to prevent hospital readmissions.
Kaiser Permanente researchers will see if a drug used to reduce risk of heart attack and stroke can also prevent or reduce complications from viral respiratory illnesses in older adults with heart disease.
In the race to find safe and effective treatments for seriously ill patients with COVID-19, Kaiser Permanente Northern California (KPNC) is enrolling patients in nationwide clinical trials and pursuing other innovative treatment options.
A JAMA study, using data on patients hospitalized in March from all 21 Kaiser Permanente Northern California hospitals, is one of the first U.S. studies to look at overall hospitalization admissions of COVID-19 patients.
5 Questions for…Dr. Michael A. Bookman, co-leader of a clinical trial that could provide an important new treatment option for women with advanced gynecological cancers.
Alan Go, MD, of the Kaiser Permanente Division of Research, and Kaiser Permanente Northern California oncologist Louis Fehrenbacher, MD, are among the less than 400 people named as Highly Cited Researchers in clinical medicine for 2017 by Clarivate Analytics. The annual list recognizes investigators whose research ranks in the top 1 percent most cited works in their field, indicating exceptional scientific impact.
